Please Wait.....
Report
Global Market Opportunities and Competitive Landscape for CDMO
Market Research Report I 2024-11-14 I 130 Pages I BCC Research
Description
Report Scope
This report provides an overview of the pharmaceutical business and the function of contract development and manufacturing organizations (CDMOs). The analysis includes a review of the global CDMO market by service type, drug molecule type and end use. It also examines the regulatory policies, standards and inspection trends of the global CDMO markets. In addition, the competitive environment, significant rivals, significant leaders and top 10 manufacturers in the CDMO sector are also reviewed.
The report presents a detailed description of the service types (API manufacturing services, drug product/finished drug manufacturing service, pharmaceutical development services and analytical testing and regulatory support services) and current and historical market revenues. The CDMO markets are also segmented based on type of molecule (small-molecule drugs, biologics and advanced therapies) and end user (clinical and commercial). The market revenue for each geographic segment (North America, Europe, Asia-Pacific and the Rest of the World) has also been provided in the report.
In order to provide an in-depth understanding of the market, profiles of market participants, competitive landscape, key competitors and respective market share are also included in this report. For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029.
Report Includes
- 76 data tables and 32 additional tables
- An overview of the global contract development and manufacturing organization (CDMO) market
- Analysis of the global market trends, with data from 2021-2022, estimates for 2023, forecast for 2024, and projections of compound annual growth rates (CAGRs) through 2029
- Estimates of the market size and revenue forecast for the CDMO market, and a corresponding market share analysis based on type of service, drug molecule type, end user, and region
- Evaluation of the market potential and opportunities for pharmaceutical CDMOs, regulatory policies, standards and inspection trends
- Identifying the pharma companies that are considered leaders in their field, as well as the technological means these companies are using to exploit their markets
- A look at the competitive landscape of the global CDMO market, featuring companies contracting with a contract manufacturing outsourcer for both clinical and commercial stage manufacturing
- A discussion of the ESG challenges and practices in the CDMO industry
- An analysis of the market shares of key companies in the industry as well as their proprietary technologies and strategic alliances
- Profiles of the leading players, including Thermo Fisher Scientific Inc., Merck KGaA, Lonza, Catalent Inc., and WuXi AppTec
Executive Summary
Summary:
The global CDMO market was valued at $128 billion in 2023. The market is expected to grow at a compound annual growth rate (CAGR) of 7.0% to reach approximately $191.6 billion by the end of 2029. The CDMO sector is dynamic and offers service providers a wealth of opportunities for expansion. As the CDMO sector is trending toward consolidation, CDMO businesses are shifting focus to become one-stop shops or integrated pharmaceutical service providers.
With comprehensive services covering the whole drug development and manufacturing process, CDMOs are essential to the pharmaceutical industry. What distinguishes CDMOs from other service providers is this end-to-end support. A CDMO can offer services like pre-formulation and formulation development in the early phases of drug development. After the drug formulation is created, the CDMO can help with stability testing as well. A CDMO can supply clinical trial materials once the drug enters the clinical trial stage. These materials consist of the investigational medicinal product (IMP) that will be given to patients throughout the study and the paperwork required to comply with regulatory requirements. Ultimately, a CDMO can increase production from clinical trial quantities to commercial-scale quantities after the drug is approved for marketing. They can also manage the final product's packaging and delivery.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Overview
Value Chain Analysis
Small-Molecule Drugs
Biologics
Advanced Therapy Medical Products
PESTEL Analysis of the Pharmaceutical Industry
Political Factors
Economic Factors
Social Factors
Technological Factors
Environmental Factors
Legal Factors
Chapter 3 Market Dynamics
Global Market Dynamics
Market Drivers
Increase in Pharmaceutical Outsourcing Practices
Pressure on R&D Spending
Rising Demand for Advanced Therapeutics
Upsurge in the Number of Clinical Trials
Market Restraints
Strict Regulations and Compliance Requirements
Shortage of Skilled Technical Personnel
Strong Competition in Cost, Technology and Service Ranges
Market Opportunities
Inorganic Growth
Chapter 4 Emerging Trends
Overview
Increased Focus on Biologics and Cell and Gene Therapy
Integration of Digital Technologies
Collaborative Risk Management
Chapter 5 Regulatory Landscape
Overview
Good Manufacturing Practice (GMP)
Quality Assurance and Quality Control
Regulatory Submissions
Environmental & Safety Regulations
International Standards
Data Integrity & Security
Labeling & Packaging
Audits and Inspections
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Market Breakdown by Type of Service
API Manufacturing Services
Drug Product/Finished Drug Manufacturing Services
Pharmaceutical Development Services
Analytical Testing and Regulatory Support Services
Market Breakdown by Type of Molecule
Small-molecule Drugs
Biologics
Advanced Therapies
Market Breakdown by End User
Clinical
Commercial
Geographic Breakdown
Market Breakdown by Region
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Competitive Intelligence
Overview
New Entrants in Market
Global Market Shares of Leading Companies
Chapter 8 Sustainability in CDMO Market: ESG Perspective
Overview
Green Chemistry and Pharmaceutical Manufacturing
Considering Sustainability through the Development Cycle and Across the Supply Chain
Sustainability in the CDMO industry
Environmental Considerations
Social Considerations
Governance Factors
ESG Risk Ratings
Conclusion
Chapter 9 Appendix
Methodology
Sources
Abbreviations
Company Profiles
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
CATALENT INC.
FUJIFILM DIOSYNTH BIOTECHNOLOGIES
LONZA
MERCK KGAA
RECIPHARM AB
SAMSUNG BIOLOGICS
SIEGFRIED HOLDING AG
THERMO FISHER SCIENTIFIC INC.
WUXI APPTEC
List of Tables
Summary Table : Global CDMO Market, by Type of Service, Through 2029
Table 1 : Global CDMO Market, by Type of Service, Through 2029
Table 2 : Global CDMO Market for API Manufacturing Services, by Region, Through 2029
Table 3 : Global CDMO Market for Drug Product/Finished Drug Manufacturing Services, by Region, Through 2029
Table 4 : Global CDMO Market for Pharmaceutical Development Services, by Region, Through 2029
Table 5 : Global CDMO Market for Analytical Testing and Regulatory Support Services, by Region, Through 2029
Table 6 : Global CDMO Market, by Type of Molecule, Through 2029
Table 7 : Global CDMO Market for Small-molecule Drugs, by Region, Through 2029
Table 8 : Global CDMO Market for Biologics, by Region, Through 2029
Table 9 : Global CDMO Market for Advanced Therapies, by Region, Through 2029
Table 10 : Global CDMO Market, by End User, Through 2029
Table 11 : Global CDMO Market for Clinical Services, by Region, Through 2029
Table 12 : Global CDMO Market for Commercial Services, by Region, Through 2029
Table 13 : Global Market for CDMO, by Region, Through 2029
Table 14 : North American CDMO Market, by Types of Service, Through 2029
Table 15 : North American CDMO Market, by Type of Molecule, Through 2029
Table 16 : North American CDMO Market, by End User, Through 2029
Table 17 : North American Market for CDMO, by Country, Through 2029
Table 18 : The U.S. CDMO Market, by Types of Service, Through 2029
Table 19 : The U.S. CDMO Market, by Type of Molecule, Through 2029
Table 20 : The U.S. CDMO Market, by End User, Through 2029
Table 21 : Canadian CDMO Market, by Types of Service, Through 2029
Table 22 : Canadian CDMO Market, by Type of Molecule, Through 2029
Table 23 : Canadian CDMO Market, by End User, Through 2029
Table 24 : Mexican CDMO Market, by Types of Service, Through 2029
Table 25 : Mexican CDMO Market, by Type of Molecule, Through 2029
Table 26 : Mexican CDMO Market, by End User, Through 2029
Table 27 : European CDMO Market, by Types of Service, Through 2029
Table 28 : European CDMO Market, by Type of Molecule, Through 2029
Table 29 : European CDMO Market, by End User, Through 2029
Table 30 : European Market for CDMO Market, by Country, Through 2029
Table 31 : German CDMO Market, by Types of Service, Through 2029
Table 32 : German CDMO Market, by Type of Molecule, Through 2029
Table 33 : German CDMO Market, by End User, Through 2029
Table 34 : The U.K. CDMO Market, by Types of Service, Through 2029
Table 35 : The U.K. CDMO Market, by Type of Molecule, Through 2029
Table 36 : The U.K. CDMO Market, by End User, Through 2029
Table 37 : French CDMO Market, by Types of Service, Through 2029
Table 38 : French CDMO Market, by Type of Molecule, Through 2029
Table 39 : French CDMO Market, by End User, Through 2029
Table 40 : Spanish CDMO Market, by Types of Service, Through 2029
Table 41 : Spanish CDMO Market, by Type of Molecule, Through 2029
Table 42 : Spanish CDMO Market, by End User, Through 2029
Table 43 : Italian CDMO Market, by Types of Service, Through 2029
Table 44 : Italian CDMO Market, by Type of Molecule, Through 2029
Table 45 : Italian CDMO Market, by End User, Through 2029
Table 46 : Rest of European Countries' CDMO Market, by Types of Service, Through 2029
Table 47 : Rest of European Countries' CDMO Market, by Type of Molecule, Through 2029
Table 48 : Rest of European Countries' CDMO Market, by End User, Through 2029
Table 49 : Asia-Pacific CDMO Market, by Types of Service, Through 2029
Table 50 : Asia-Pacific CDMO Market, by Type of Molecule, Through 2029
Table 51 : Asia-Pacific CDMO Market, by End User, Through 2029
Table 52 : Asia-Pacific Market for CDMO, by Country, Through 2029
Table 53 : Chinese CDMO Market, by Types of Service, Through 2029
Table 54 : Chinese CDMO Market, by Type of Molecule, Through 2029
Table 55 : Chinese CDMO Market, by End User, Through 2029
Table 56 : Japanese CDMO Market, by Types of Service, Through 2029
Table 57 : Japanese CDMO Market, by Type of Molecule, Through 2029
Table 58 : Japanese CDMO Market, by End User, Through 2029
Table 59 : Indian CDMO Market, by Types of Service, Through 2029
Table 60 : Indian CDMO Market, by Type of Molecule, Through 2029
Table 61 : Indian CDMO Market, by End User, Through 2029
Table 62 : Rest of Asia-Pacific CDMO Market, by Types of Service, Through 2029
Table 63 : Rest of Asia-Pacific CDMO Market, by Type of Molecule, Through 2029
Table 64 : Rest of Asia-Pacific CDMO Market, by End User, Through 2029
Table 65 : Rest of the World CDMO Market, by Types of Service, Through 2029
Table 66 : Rest of the World CDMO Market, by Type of Molecule, Through 2029
Table 67 : Rest of the World CDMO Market, by End User, Through 2029
Table 68 : ESG Risk Rankings for CDMO Companies, 2024*
Table 69 : Information Sources in this Report
Table 70 : Glossary of Terms Used in the Global CDMO Market
Table 71 : Boehringer Ingelheim International GmbH: Company Snapshot
Table 72 : Boehringer Ingelheim International GmbH: Financial Performance, FY 2022 and 2023
Table 73 : Boehringer Ingelheim International GmbH: Product Portfolio
Table 74 : Boehringer Ingelheim International GmbH: News/Recent Developments, 2021
Table 75 : Catalent Inc.: Company Snapshot
Table 76 : Catalent Inc.: Financial Performance, FY 2022 and 2023
Table 77 : Catalent Inc.: Product Portfolio
Table 78 : Catalent Inc.: News/Key Developments, 2022-2024
Table 79 : Fujifilm Diosynth Biotechnologies: Company Snapshot
Table 80 : Fujifilm Diosynth Biotechnologies: Product Portfolio
Table 81 : Fujifilm Diosynth Biotechnologies: News/Key Developments, 2021-2024
Table 82 : Lonza: Company Snapshot
Table 83 : Lonza: Financial Performance, FY 2022 and 2023
Table 84 : Lonza: Product Portfolio
Table 85 : Lonza: News/Key Developments, 2022?2024
Table 86 : Merck KGaA: Company Snapshot
Table 87 : Merck KGaA: Financial Performance, FY 2022 and 2023
Table 88 : Merck KGaA: Product Portfolio
Table 89 : Merck KGaA: News/Key Developments, 2022
Table 90 : Recipharm AB: Company Snapshot
Table 91 : Recipharm AB: Product Portfolio
Table 92 : Recipharm AB: News/Key Developments, 2021-2024
Table 93 : Samsung Biologics: Company Snapshot
Table 94 : Samsung Biologics: Financial Performance, FY 2022 and 2023
Table 95 : Samsung Biologics: Product Portfolio
Table 96 : Samsung Biologics: News/Key Developments, 2021-2024
Table 97 : Siegfried Holding AG: Company Snapshot
Table 98 : Siegfried Holding AG: Financial Performance, FY 2022 and 2023
Table 99 : Siegfried Holding AG: Product Portfolio
Table 100 : Siegfried Holding AG: News/Key Developments, 2022-2024
Table 101 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 102 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
Table 103 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 104 : WuXi AppTec: Company Snapshot
Table 105 : WuXi AppTec: Financial Performance, FY 2022 and 2023
Table 106 : WuXi AppTec: Product Portfolio
Table 107 : WuXi AppTec: News/Key Developments, 2022-2024
List of Figures
Summary Figure : Global CDMO Market, by Type of Service, 2021-2029
Figure 1 : Pharma Services Value Chain
Figure 2 : Market Dynamics of Global CDMO Market
Figure 3 : Global CDMO Market Share, by Type of Service, 2023
Figure 4 : Global CDMO Market Share for API Manufacturing Services, by Region, 2023
Figure 5 : Global CDMO Market Share for Drug Product/Finished Drug Manufacturing Services, by Region, 2023
Figure 6 : Global CDMO Market Share for Pharmaceutical Development Services, by Region, 2023
Figure 7 : Global CDMO Market Share for Analytical Testing and Regulatory Support Services, by Region, 2023
Figure 8 : Global CDMO Market Share, by Type of Molecule, 2023
Figure 9 : Small-molecule NCE and Biologics Approved by FDA, 2018-2023
Figure 10 : Global CDMO Market Share for Small-molecule Drugs, by Region, 2023
Figure 11 : Global CDMO Market Share for Biologics, by Region, 2023
Figure 12 : Global CDMO Market Share for Advanced Therapies, by Region, 2023
Figure 13 : Global CDMO Market Share, by End User, 2023
Figure 14 : Global CDMO Market Share for Clinical Services, by Region, 2023
Figure 15 : Global CDMO Market Share for Commercial Services, by Region, 2023
Figure 16 : Global CDMO Market Share, by Region, 2023
Figure 17 : North American CDMO Market Share, by Types of Service, 2023
Figure 18 : North American CDMO Market Share, by Type of Molecule, 2023
Figure 19 : North American CDMO Market Share, by End User, 2023
Figure 20 : North American CDMO Market Share, by Country, 2023
Figure 21 : European CDMO Market Share, by Types of Service, 2023
Figure 22 : European CDMO Market Share, by Type of Molecule, 2023
Figure 23 : European CDMO Market Share, by End User, 2023
Figure 24 : European CDMO Market Share, by Country, 2023
Figure 25 : Asia-Pacific CDMO Market Share, by Types of Service, 2023
Figure 26 : Asia-Pacific CDMO Market Share, by Type of Molecule, 2023
Figure 27 : Asia-Pacific CDMO Market Share, by End User, 2023
Figure 28 : Asia-Pacific CDMO Market Share, by Country, 2023
Figure 29 : Rest of the World CDMO Market Share, by Types of Service, 2023
Figure 30 : Rest of the World CDMO Market Share, by Type of Molecule, 2023
Figure 31 : Rest of the World CDMO Market Share, by End User, 2023
Figure 32 : Global Company Share Analysis of CDMO, 2023
Figure 33 : Boehringer Ingelheim International GmbH: Revenue Share, by Business Unit, FY 2023
Figure 34 : Boehringer Ingelheim International GmbH: Revenue Share, by Region/Country, FY 2023
Figure 35 : Catalent Inc.: Revenue Share, by Business Unit, FY 2023
Figure 36 : Catalent Inc.: Revenue Share, by Country/Region, FY 2023
Figure 37 : Lonza: Revenue Share, by Business Unit, FY 2023
Figure 38 : Lonza: Revenue Share, by Country/Region, FY 2023
Figure 39 : Merck KGaA: Revenue Share, by Business Unit, FY 2023
Figure 40 : Merck KGaA: Revenue Share, by Country/Region, FY 2023
Figure 41 : Samsung Biologics: Revenue Share, by Business Unit, FY 2023
Figure 42 : Samsung Biologics: Revenue Share, by Country/Region, FY 2023
Figure 43 : Siegfried Holding AG: Revenue Share, by Business Unit, FY 2023
Figure 44 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2023
Figure 45 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2023
Figure 46 : WuXi AppTec: Revenue Share, by Business Unit, FY 2023
Figure 47 : WuXi AppTec: Revenue Share, by Country/Region, FY 2023
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security